Summary
Berberine is the major constituent of Coptis chinese and is commonly used in Chinese herbal medicine to treat patients with gastrointestinal disorders. In this study, using flow cytometry, we have found that a 24-h berberine treatment up-regulated the multidrug-resistant transporter (pgp-170) expression in two oral (KB, OC2), two gastric (SC-M1, NUGC-3) and two colon (COLO 205, CT 26) cancer cell lines. Decreased retention of rhodamine 123 was observed in berberine-treated cells as compared to vehicle control. To examine whether the berberine modulated pgp-170 expression in cancer cells is associated with changes in drug resistance, we determined the cytotoxicity, cell cycle progression and cell morphology of Paclitaxel-treated cells. Paclitaxel (1 nM–10 μM) treatment for 24 h induced cytotoxicity in OC2, SC-M1 and COLO 205 cells in a dose-dependent manner. Pretreatment of cells with 32 μM berberine for 24 h prior to Paclitaxel treatment resulted in increased viability as compared to that of Paclitaxel-treated cells. In addition, Paclitaxel-induced apoptosis and/or G2/M arrest in these three cancer cell lines. Pretreatment of cells with berberine prior to Paclitaxel blocked the Paclitaxel-induced cell cycle responses and morphological changes. These results together suggest that berberine modulated the expression and function of pgp-170 that leads to reduced response to Paclitaxel in digestive track cancer cells.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ajani, JA, Ilson, D, Daugherty, K, Pazdur, R & Kelsen, DP (1994). Taxol (Paclitaxel) is active against carcinoma of the esophagus: report of Phase II trial. Proc Am Soc Clin Oncol 13: 192.
Akutsu, M, Kano, Y, Tsunoda, S, Suzuki, K, Yazawa, Y & Miura, Y (1995). Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. Eur J Cancer 31A: 2341–2346.
Anonymous (1997). Paclitaxel and docetaxel in breast and ovarian cancer. Drug Ther Bull 35: 43–46.
Belani, CP (1998). Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer. Oncology 12: 74–79.
Catherine, MW, Jian, Z, Patricia, A, McQueney, DB & Elias, L (1995). Paclitaxel-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1: 506–526.
Chabner, BA (1991). Paclitaxel. Princ Pract Oncol 5: 1–10.
Chang, YF, Li, LL, Wu, CW, Liu, TY, Lui, WY, P’eng, FK & Chi, CW (1996). Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77: 14–18.
Chao, Y, Chan, WK, Birkhofer, MJ, Hu, OP, Wang, SS, Huang, YS, Liu, M, Whang-Peng, J, Chi, KH, Lui, WY & Lee, SD (1998). Phase II and pharmocokinetic study of Paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 78: 34–39.
Chaudhary, PM & Roninson, IB (1991). Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85–94.
Chi, CW, Chang, YF, Chao, TW, Chiang, SH, P’eng, FK, Lui, WY & Liu, TY (1994). Flowcytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. Life Sci 45: 2099–2107.
Cloud-Heflin, BA, McMaster, RA, Osborn, MT & Chamber, TC (1996). Expression, subcellular distribution and response to phorbol esters of protein kinase C (PKC) isozymes in drug-sensitive and multidrug-resistant KB cells evidence for altered regulation of PKC-alpha. Eur J Biochem 239: 796–804.
Creasey, WA (1979). Biochemical effects of berberine. Biochem Pharm 28: 1081–1084.
Duan, Z, Feller, A, Makastorsis, T & Seiden, MV (1997). Identification of a novel gene associated with Paclitaxel resistance in human cancer cells by differential display. Proc Am Assoc Cancer Res 38: 482.
Dumontet, C, Duran, GE, Steger, KA, Beketic-Oreskovic, L & Siki, BI (1996). Resistance mechanisms in human sarcoma mutants derived by single-step exposure to Paclitaxel (Taxol). Cancer Res 56: 1091–1097.
Dustin, P (1980). Microtubule. Sci Am 243: 66–76.
Einzig, AI, Wiemik, PH, Lipsitz, S & Benson, AB (1993). Phase II trial of Paclitaxel in patients with adenocarcinoma of the upper gastrointestinal track (UGIT): the Eastern Cooperation Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 12: 194.
Frankel, A, Buckman, R & Kerbel, RS (1997). Abrogation of Paclitaxel-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 57: 2388–2393.
Gant, TW, Silverman, JA & Thorgeirsson, SS (1992). Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a trans-acting transcriptional repressor. Nucleic Acids Res 20: 2841–2846.
Goldstein, LJ (1996). MDR1 gene expression in solid tumor. Eur J Cancer 32: 1039–1050.
Jenning, BR & Ridler, PJ (1983). Interaction of chromosomal stains with DNA. An electrofluorescence study. Biophys Struct Mech 10: 71–79.
Jin, L, Meng, CL, Han, SH, Ding, MJ, Chang, TM & Chen, VTK (1987). A study on production of monoclonal antibodies using SC-M1 cells as immunogen. J Med Sci 8: 17–25.
Kano, Y, Akutsu, M, Tsunoda, S, Ando, J, Matsu, J, Suzuki, K, Inoue, Y & Adachi, KI (1996a). Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704–710.
Kano, Y, Akutsu, M, Tsunoda, S, Suzuki, K & Yazawa, Y (1996b). In vitro schedule-dependent interaction between paclitaxel and cisptatin in human carcinoma cell lines. Cancer Chemother Pharmacol 37: 525–530.
Kiehntopf, M, Brach, MA, Licht, T, Petschauer, S, Karawajew, L, Kirschning, C & Herrmann, F (1994). Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J 13: 4645–4652.
Kool, M, Haas, MD, Scheffer, GL, Scheper, RJ, van Eijk, MJT, Juijn, JA, Baas, F & Borst, P (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537–3547.
Kuo, CL, Chou, CC & Yung, YM (1995). Berberine complex with DNA in the berberine-induced apoptosis in human leukemia HL-60 cells. Cancer Lett 93: 193–200.
Liebmann, JE, Hahn, SM, Cook, JA, Lipschultz, C, Mitchell, JB & Kaufman, DC (1993). Glutathione depletion by L-buthionine sulfoximine antagonized Paclitaxel cytotoxicity. Cancer Res 53: 2066–2070.
Lin, HL, Chang, YF, Liu, TY, Wu, CW & Chi, CW (1998). Submicromolar Paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. Anticancer Res 18: 3443–3450.
Lin, HL, Liu, TY, Lui, WY & Chi, CW (1999). Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. Cancer 85: 1937–1942.
Ludescher, C, Thaler, J, Drach, D, Drach, J, Spitaler, M, Gattringer, C, Huber, H & Hofmann, J (1992). Detection of activity of P-glycoprotein in human tumor samples using rhodamine 123. Br J Haematol 82: 161–168.
Milross, CG, Mason, KA, Hunter, NR, Chung, WK, Peter, LJ & Milas, L (1996). Relationship of mitotic arrest and apoptosis to antitumor effect of Paclitaxel. J Natl Cancer Inst 88: 1308–1314.
Nishino, H, Kitagawa, K, Fujiki, H & Iwashima, A (1986). Berberine sulfate inhibits tumor-promoting activity of teleocidin in two-stage carcinogenesis on mouse skin. Oncology 43: 131–134.
Petriz, J & Garcia-Lopez, J (1997). Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 11: 1124–1130.
Rowinsky, EK, Cazenave, LA & Donehower, RC (1990). Paclitaxel: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247–1259.
Rowinsky, EK & Donehower, RC (1991). Paclitaxel: twenty years later, the story unfold. J Natl Cancer Inst 83: 1778–1781.
Rowinsky, EK, Onetto, N, Canetta, RM & Arbuck, SG (1992). Paclitaxel: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19: 646.
Salvioli, S, Ardizzoni, A, Franceschi, C & Cossarizza, A (1997). JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess DY changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 411: 77–82.
Schuetz, JD, Strom, SC & Schuetz, EG (1995). Induction of P-glycoprotein mRNA by protein synthesis inhibition is not controlled by a transcriptional repressor protein in rat and human liver cells. J Cell Physiol 165: 261–272.
Sekiguchi, M, Sakakibara, K & Fuji, G (1978). Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn J Exp Med 48: 61–68.
Slichenmyer, WJ & Von Hoff, DD (1991). Paclitaxel: a new effective anti-cancer drug. Anticancer Drug 2: 519–530.
Sun, D, Abraham, SN & Beachey, EH (1988). Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesion in uropathogenic Escherichia coli. Antimicrob Agents Chemother 32: 1274–1277.
Taira, Z, Matsumoto, M, Ishida, S, Ichikawa, T & Sakiya, Y (1994). Aggregation of DNA enhanced by protoberberine alkaloids, coralyne and berberine. Chem Pharm Bull 42: 1556–1561.
Vikhanskaya, F, Vignati, S, Beccaglia, P, Ottoboni, C, Russo, P, D’Incalci, M & Broggini, M (1998). Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to Paclitaxel by induction G2/M arrest and apoptosis. Exp Cell Res 241: 96–101.
Watt, G, Long, GW, Grogl, M & Martin, SK (1990). Reversal of drug-resistant falciparum malaria by calcium antagonists: potential for host cell toxicity. Trans R Soc Trop Med Hyg 84: 187–190.
Wilson, L (1975). Microtubules as drug receptor: pharmacological properties of microtubule protein. Ann NY Acad Sci 253: 213–231.
Wong, YK, Chang, KW, Chen, CF & Chang, CS (1990). Characterization of 2 new cell lines derived from oral cavity human squamous cell carcinoma OC-1 and OC-2. J Oral Maxillofac Surg 48: 385–390.
Yang, IW, Chou, CC & Yung, BY (1996). Dose-dependent effects of berberine on cell cycle pause and apoptosis in Balb/c 3T3 cells. Naunyn-Schmiedebergs Arch Pharmacol 354: 102–108.
Zhang, RX, Dougherty, DV & Rosenblum, ML (1990). Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors. Chin Med J 103: 658–665.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Lin, HL., Liu, TY., Wu, CW. et al. Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel. Br J Cancer 81, 416–422 (1999). https://doi.org/10.1038/sj.bjc.6690710
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690710
Keywords
This article is cited by
-
Herbal Medicines for the Treatment of Nonalcoholic Steatohepatitis
Current Hepatology Reports (2021)
-
Prevention and Treatment of Colorectal Cancer by Natural Agents from Mother Nature
Current Colorectal Cancer Reports (2013)
-
Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line
Cancer Chemotherapy and Pharmacology (2008)
-
Reversal mechanism of arsenic trioxide in the drug resistance of human gastric cancer cell line SGC7901/ADR
The Chinese-German Journal of Clinical Oncology (2007)
-
Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL
Archives of Toxicology (2007)
